Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 5
2012 3
2013 1
2014 1
2015 2
2016 1
2017 1
2018 1
2019 2
2020 3
2021 1
2022 3
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Grade 1 Other Gastrointestinal, CTCAE"
Page 1
Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial.
Kishan AU, Ma TM, Lamb JM, Casado M, Wilhalme H, Low DA, Sheng K, Sharma S, Nickols NG, Pham J, Yang Y, Gao Y, Neylon J, Basehart V, Cao M, Steinberg ML. Kishan AU, et al. JAMA Oncol. 2023 Mar 1;9(3):365-373. doi: 10.1001/jamaoncol.2022.6558. JAMA Oncol. 2023. PMID: 36633877 Free PMC article.
Secondary outcomes included CTCAE v4.03-based gastrointestinal toxic effects and International Prostate Symptom Score (IPSS)-based and Expanded Prostate Cancer Index Composite-26 (EPIC-26)-based outcomes. ...The incidence of acute grade 2 or greater GU …
Secondary outcomes included CTCAE v4.03-based gastrointestinal toxic effects and International Prostate Symptom Score ( …
Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.
Corti F, Brizzi MP, Amoroso V, Giuffrida D, Panzuto F, Campana D, Prinzi N, Milione M, Cascella T, Spreafico C, Randon G, Oldani S, Leporati R, Scotto G, Pulice I, Stocchetti BL, Porcu L, Coppa J, Di Bartolomeo M, de Braud F, Pusceddu S. Corti F, et al. BMC Cancer. 2023 Sep 26;23(1):908. doi: 10.1186/s12885-023-11287-2. BMC Cancer. 2023. PMID: 37752423 Free PMC article.
In stage I, the primary objective is to find the optimal dose of cabozantinib in combination with lanreotide and to evaluate the safety of the combination (percentage of patients experiencing grade 3-5 toxicities according to NCI-CTCAE version 5.0). Starting dose of …
In stage I, the primary objective is to find the optimal dose of cabozantinib in combination with lanreotide and to evaluate the safety of t …
Phase 1 trial of CV301 in combination with anti-PD-1 therapy in nonsquamous non-small cell lung cancer.
Rajan A, Gray JE, Devarakonda S, Birhiray R, Korchin B, Menius E, Donahue RN, Schlom J, Gulley JL. Rajan A, et al. Int J Cancer. 2023 Feb 1;152(3):447-457. doi: 10.1002/ijc.34267. Epub 2022 Sep 9. Int J Cancer. 2023. PMID: 36054490 Free PMC article. Clinical Trial.
Mean treatment duration was 332 days in C1 and 289 days in C2. CTCAE grade 3 adverse events (AEs) were observed in four (100%) patients in C1 and three (37.5%) patients in C2. ...Immune-related AEs (irAEs) fulfilling criteria for a dose-limiting toxicity incl …
Mean treatment duration was 332 days in C1 and 289 days in C2. CTCAE grade 3 adverse events (AEs) were observed in four …
A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy.
Kotaka M, Saito Y, Kato T, Satake H, Makiyama A, Tsuji Y, Shinozaki K, Fujiwara T, Mizushima T, Harihara Y, Nagata N, Kurihara N, Ando M, Kusakawa G, Sakai T, Uchida Y, Takamoto M, Kimoto S, Hyodo I. Kotaka M, et al. Cancer Chemother Pharmacol. 2020 Nov;86(5):607-618. doi: 10.1007/s00280-020-04135-8. Epub 2020 Sep 23. Cancer Chemother Pharmacol. 2020. PMID: 32965539 Free PMC article. Clinical Trial.
RESULTS: Seventy-nine participants (placebo n = 28, 1-day ART n = 27, 3-day ART n = 24) received study drugs. The least-squares mean FACT/GOG-Ntx-12 scores at cycle 12 from the mixed effect model for repeated measures were 28.9 with placebo, 36.3 with 1-day A …
RESULTS: Seventy-nine participants (placebo n = 28, 1-day ART n = 27, 3-day ART n = 24) received study drugs. The least-squares mean …
A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient.
Botticelli A, Onesti CE, Strigari L, Occhipinti M, Di Pietro FR, Cerbelli B, Petremolo A, Anselmi E, Macrini S, Roberto M, Falcone R, Lionetto L, Borro M, Milano A, Gentile G, Simmaco M, Marchetti P, Mazzuca F. Botticelli A, et al. Anticancer Drugs. 2017 Jun;28(5):551-556. doi: 10.1097/CAD.0000000000000492. Anticancer Drugs. 2017. PMID: 28296649
Grade 3-4 toxicities were observed in 118 (18.4%) patients and were most frequently observed in patients with altered 5-FU degradation rate (43.5 and 26.7% of the patients in the poor metabolizer and in the ultrarapid metabolizer group respectively, vs. 17% i …
Grade 3-4 toxicities were observed in 118 (18.4%) patients and were most frequently observed in patients with altered 5 …
Stomach Dose-Volume Predicts Acute Gastrointestinal Toxicity in Chemoradiotherapy for Locally Advanced Pancreatic Cancer.
Holyoake DLP, Warren DR, Hurt C, Aznar M, Partridge M, Mukherjee S, Hawkins MA. Holyoake DLP, et al. Clin Oncol (R Coll Radiol). 2018 Jul;30(7):418-426. doi: 10.1016/j.clon.2018.02.067. Epub 2018 Mar 28. Clin Oncol (R Coll Radiol). 2018. PMID: 29602584 Clinical Trial.
The risk of CTCAE grade 2 events was modelled using multivariable logistic regression and prediction of severity grade using ordinal regression. RESULTS: CTCAE grade 2 symptoms occurred in 38 patients (42%). On univariate analysis, stomac …
The risk of CTCAE grade 2 events was modelled using multivariable logistic regression and prediction of severity gra …
Management of sorafenib-related adverse events: a clinician's perspective.
Brose MS, Frenette CT, Keefe SM, Stein SM. Brose MS, et al. Semin Oncol. 2014 Feb;41 Suppl 2:S1-S16. doi: 10.1053/j.seminoncol.2014.01.001. Epub 2014 Jan 9. Semin Oncol. 2014. PMID: 24576654 Free article.
Sorafenib-related adverse events (AEs) that commonly occur across these tumor types include hand-foot skin reaction (HSFR), rash, upper and lower gastrointestinal (GI) distress (ie, diarrhea), fatigue, and hypertension. These commonly range from grade 1 to 3, …
Sorafenib-related adverse events (AEs) that commonly occur across these tumor types include hand-foot skin reaction (HSFR), rash, upper and …
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.
Nicolini S, Bodei L, Bongiovanni A, Sansovini M, Grassi I, Ibrahim T, Monti M, Caroli P, Sarnelli A, Diano D, Di Iorio V, Grana CM, Cittanti C, Pieri F, Severi S, Paganelli G. Nicolini S, et al. Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3260-3267. doi: 10.1007/s00259-021-05236-z. Epub 2021 Feb 18. Eur J Nucl Med Mol Imaging. 2021. PMID: 33604690 Free PMC article. Clinical Trial.
Treatment response was assessed per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1). Toxicity was assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. ...Grade 3 (G3) or 4 (G4) hematologic …
Treatment response was assessed per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1). Toxi …
Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F.
Damodaran S, Zhao F, Deming DA, Mitchell EP, Wright JJ, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Suga JM, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Damodaran S, et al. J Clin Oncol. 2022 May 10;40(14):1552-1561. doi: 10.1200/JCO.21.01648. Epub 2022 Feb 8. J Clin Oncol. 2022. PMID: 35133871 Free PMC article. Clinical Trial.
The most common reason for protocol discontinuation was disease progression (n = 17, 68%). Grade 3/4 toxicities observed were consistent with reported toxicities for PI3K pathway inhibition. Sixteen patients (53%) had grade 3 toxicities, and one patient (3%) …
The most common reason for protocol discontinuation was disease progression (n = 17, 68%). Grade 3/4 toxicities observed were …
Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre.
Lau DK, Fong C, Arouri F, Cortez L, Katifi H, Gonzalez-Exposito R, Razzaq MB, Li S, Macklin-Doherty A, Hernandez MA, Hubank M, Fribbens C, Watkins D, Rao S, Chau I, Cunningham D, Starling N. Lau DK, et al. BMC Cancer. 2023 Apr 26;23(1):380. doi: 10.1186/s12885-023-10857-8. BMC Cancer. 2023. PMID: 37101114 Free PMC article.
METHODS: Patients receiving fluoropyrimidine chemotherapy for gastrointestinal cancer prior to, and following the implementation of DPYD testing were identified retrospectively. ...Mean relative dose intensity for the first dose was 54.2% (range 37.5-75%) for DPYD heterozy …
METHODS: Patients receiving fluoropyrimidine chemotherapy for gastrointestinal cancer prior to, and following the implementation of D …
26 results